Cite

HARVARD Citation

    Udagawa, H. et al. (2019). Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung cancer. pp. 145-150. [Online]. 
  
Back to record